Jun 13, 2022 / 10:20PM GMT
Paul Choi - Goldman Sachs Group, Inc. - Analyst
Maybe to start, Adrian, for those who are unfamiliar with Foghorn, can you maybe provide an overview of what is the gene traffic control platform and the various modalities and approaches that you employ to target the chromatin regulatory system?
Questions and Answers:
Adrian Gottschalk - Foghorn Therapeutics Inc. - President & CEOSure. Great. Thank you, Paul, and thanks to you and Goldman Sachs for having me here. My voice goes [about]; let me take a sip of water. The big idea behind Foghorn is one of altering and modulating gene expression through this chromatin regulatory system and to use maybe a simplifying analogy and the type of biology that we're working on and then I'll step through the modalities of how we think about the opportunity.
The analogy I often use is one of the architect and blueprint where if the genes are the blueprints, obviously, of the cell, then the chromatin regulatory system is the actual architect. And so, you can imagine if one hijacks the architect as what
Trustpilot
